Abstract. Invertebrate models of several human neurodegenerative diseases have recently been described. These models faithfully replicate key neuropathological features of the human disorders. Because the basic cell biology of the nervous system is very similar in vertebrates and invertebrates, the sophisticated and rapid genetic analysis feasible in Drosophila and C. elegans promises significant insight into human neurodegenerative syndromes. In addition, the short lifespan, small size, and ease of culturing make worms and flies ideal for drug testing.
INTRODUCTION
Animal models provide critical testing grounds for both models of disease pathogenesis and potential therapeutic agents. Vertebrates, particularly mice, have provided many useful models of nervous system diseases. However, genetic analysis in vertebrate systems is still slow in comparison with simpler organisms like the nematode Caenorhabditis elegans, or the fruit fly Drosophila melanogaster. Recent insight into the molecular basis of human diseases, and in particular neurodegenerative diseases, has motivated the production of faithful invertebrate models of neurologic diseases.
Modeling diseases in simple invertebrate systems is attractive because genetic interactions can be used to define cellular cascades mediating, for example, death of dopaminergic neurons in Parkinson disease. The obvious differences between mammals and invertebrates represent potential pitfalls to modeling complex human disorders like neurodegenerative diseases in flies or worms. Fortunately, despite marked anatomic divergence, basic cell biological processes are highly conserved between the 2 classes of organisms. Processes as diverse as development and learning and memory not only share mechanistic similarities between vertebrates and invertebrates, but also often show conservation at the level of specific second messenger systems and transcription factors as well. With the sequencing of the entire genomes of C. elegans and Drosophila, similarities can now be evaluated on the whole genome level. Orthologs exist for many proteins involved in human neurologic diseases (Table 1) (1).
Worms and flies have dominated invertebrate models of human disease. Both C. elegans and Drosophila have the rapid generation time, well-developed genetics, and transgenic technology required to select mutations based on phenotype, define interacting loci, and express human genes of interest. The 2 organisms are complementary in many ways. The C. elegans nervous system is simpler than the Drosophila nervous system. In C. elegans, each neuron can be identified individually. More sophisticated behaviors may be monitored in Drosophila, correlating with the additional complexity of the nervous system. Worms live 3 wk, while flies have a life span of 2 months. Transgenic animals are relatively easy to produce in both system, but ''knock-in'' technology is primitive in both systems. A variety of techniques exist to modulate transgene expression. Tissue specific and inducible promotors are widely available, allowing tissue and developmentally specific effects to be defined.
Several approaches have been taken to modeling human diseases in invertebrates. If an ortholog is known from sequence information (Table 1) , mutations can be identified in the invertebrate gene, phenotypes sought, and biochemical cascades defined. Human counterparts of novel components of the cellular pathways delineated in the invertebrate model organism will be attractive candidates for roles in the human disorder. In practice, substantial insights often obtain when a gene mutated in a human disease is cloned and immediately identified as a component of a well-characterized invertebrate genetic pathway.
Traditional genetics relies on phenotypes rather than sequence information. Novel mutations are produced that show features of a specific disease process. The causative genetic defects may then be relevant to neurologic disorders with the same characteristics. For instance, if mutant flies are selected for adult onset degeneration of the nervous system, human homologs of the Drosophila gene products are plausible candidates for involvement in neurodegenerative diseases.
Alternatively, more directed strategies may be employed. If human disease gene products are toxic, relevant models may be produced by simply expressing the human protein in the model organism. linked to neurodegenerative diseases has provided the best invertebrate models in terms of both fidelity to the human disorder, and subsequent genetic insights (Table  2) .
Parkinson Disease
Mutations in the ␣-synuclein gene have been linked to familial Parkinson disease (2, 3) . ␣-synuclein is an abundant neuronal protein of unknown function that does not have a clear ortholog in Drosophila or C. elegans (1) . Modeling Parkinson disease by manipulating the endogenous ␣-synuclein gene in invertebrates is therefore not an attractive option. However, if disease is produced in humans by the action of a toxic protein, it may not be necessary or even desirable, to manipulate the invertebrate homolog of the human disease-related gene. Instead, expression of the toxic human protein model organism may model the disorder. It is not clear that mutations in ␣-synuclein cause Parkinson disease through a toxic mechanism; however, the dominant mode of inheritance is consistent with a gain of function property. In addition, ␣-synuclein is a prominent component of Lewy bodies, the abnormal neuronal cytoplasmic inclusion characteristic of Parkinson disease. Thus, abnormal aggregation of the protein may be related to disease pathogenesis. ␣-synuclein is present in Lewy bodies not only in the rare familial cases of Parkinson disease linked to mutation in the ␣-synuclein gene, but also in inclusions in the much more common sporadic form of the disease as well. A common mechanism may therefore operate in the familial and sporadic forms of the disease. The effects of expressing human ␣-synuclein in Drosophila (4) and mice (5) support these speculations.
When normal or mutant human ␣-synuclein is expressed in the nervous system of flies, 3 features of Parkinson disease are reproduced: adult-onset loss of dopaminergic neurons, filamentous intraneuronal inclusions containing ␣-synuclein, and progressive locomotor dysfunction. Dopaminergic neurons degenerate at about 30 days of age in the transgenic flies. Since flies live only 60 days, the effects of genetic manipulation, like expression of human ␣-synuclein, can be observed over the entire lifespan of the organism in a relatively short period of time. Nonneuronal cells are not affected by expression of normal or mutant human ␣-synuclein.
The effect on dopaminergic neurons is at least relatively specific. The majority of non-dopaminergic neurons are spared in aged transgenic flies. There is also specificity for particular subsets of dopaminergic neurons. Dopaminergic neurons in the dorsomedial region of the fly's brain appear particularly vulnerable to the effect of human ␣-synuclein. In Parkinson disease, subsets of dopaminergic neurons within the substantia nigra also show selective vulnerability. Cells in the ventral lateral portion of the nucleus are more liable to degeneration than neurons in other areas. The molecular basis of enhanced susceptibility of certain dopaminergic neurons in Parkinson disease is unknown. The presence of a similar phenomena in the Drosophila model suggests that the molecular basis of increased susceptibility within subsets of dopaminergic neurons may be amenable to genetic analysis.
␣-synuclein containing cytoplasmic inclusion bodies are formed in transgenic Drosophila (Fig. 1B) . The staining pattern for ␣-synuclein is initially diffuse and cytoplasmic in transgenic flies (Fig. 1A) ; however, over time ␣-synuclein immunoreactive puncta appear (Fig. 1B) . The time course of inclusion formation roughly parallels dopaminergic neuronal loss, suggesting that the 2 phenomena may be causally related. On electron microscopic analysis, the ␣-synuclein inclusions are found in neuronal cell bodies and are composed of filaments with diameters from 7 to 10 nm, admixed with granular material similar to human Lewy bodies.
Loss of dopaminergic neurons and inclusion formation is accompanied by locomotor dysfunction. Flies normally exhibit vigorous climbing activity when subjected to a gentle tap. Over time, ␣-synuclein transgenic flies lose their climbing ability more rapidly than normal flies. These findings demonstrate a behavioral consequence of expressing human ␣-synuclein in Drosophila, plausibly mediated by loss of dopaminergic neurons and/or inclusion formation. All 3 phenomena, dopaminergic neurodegeneration, inclusion formation, and locomotor dysfunction occur over the same time course. In addition, all 3 abnormalities manifest with expression of normal as well as mutant human ␣-synuclein, supporting a common pathogenetic mechanism in idiopathic Parkinson disease and the rare familial variants linked to mutations in the ␣-synuclein gene. Expression of human ␣-synuclein in transgenic mice also produces dopaminergic degeneration, ␣-synuclein inclusion formation, and locomotor abnormalities (5) .
Although dopaminergic neurons appear particularly sensitive to ␣-synuclein toxicity in flies, other cells in the nervous system of transgenic Drosophila can also be affected by expression of human ␣-synuclein. Expression of normal or mutant ␣-synuclein specifically in the retina produces age dependent retinal degeneration. Thus, in flies, as in people, ␣-synuclein-related degenerative changes show relative rather than absolute specificity for dopaminergic neurons. The Drosophila retina is probably somewhat resistant to ␣-synuclein toxicity because about 5-fold more transgenic ␣-synuclein is produced in the eye than the brain. The presence of retinal degeneration in ␣-synuclein transgenic flies is an important technical advantage. Harnessing the powerful genetics of invertebrate model organisms is the ultimate goal of modeling human neurodegenerative diseases in these animals. In practice, this means creating additional mutations that modify relevant phenotypes. Large numbers of randomly generated mutations must be examined to identify the infrequent mutations that modify ␣-synuclein toxicity. An easily detected phenotype, ideally one that can be tested quickly in live flies, is required for successful generation of sufficient modifiers to delineate biochemical cascades. Molecular cloning of such modifiers should identify novel proteins mediating ␣-synuclein toxicity in Drosophila. The strong conservation between vertebrate and invertebrate systems suggests that mammalian homologs of Drosophila modifiers will encode proteins important in the pathogenesis of the human disorder. Invertebrate models will thus act as discovery tools to identify molecules underlying pathology in human disease. A critical test of this scheme is identification of genetic mutations in mammalian homologs of genes identified in invertebrates in familial forms of the human disease. Thus, mammalian homologs of modifiers of ␣-synuclein toxicity defined in Drosophila will be candidates for Parkinson disease mutations.
Polyglutamine Expansion Disorders: Huntington Disease and the Spinocerebellar Ataxias
Direct expression of a toxic human protein in invertebrates has provided a number of useful models of disorders caused by the expansion of polyglutamine-encoding CAG repeat sequences (6) (7) (8) . Diseases such as Huntington disease and the autosomal dominant cerebellar ataxias are caused by expansion of a trinucleotide sequence within the coding region of unrelated proteins. The expanded sequence encodes polyglutamine stretches. The toxic dominant nature of CAG expansion mutations has been established in mouse models. In transgenic mice, expression of the expanded, but not unexpanded, protein produces toxicity. Inactivation of the mouse homologs does not mimic the human disease. The strong genetic evidence for a toxic dominant gain of function mechanism encouraged several groups to model polyglutamine disorders in invertebrates. Warrick et al (6) demonstrated that expanded, but not unexpanded, ataxin-3 produces age-dependent degeneration of the Drosophila retina. Although both neuronal and nonneuronal tissue is affected by expression of expanded ataxin, neurons appear particularly vulnerable to the toxic action of the mutant protein. The retinal abnormality can be at least partially rescued by expression of the baculovirus antiapoptotic protein p35, suggesting that cell death occurs via an apoptotic mechanism. In contrast, expression of expanded huntingtin in the Drosophila eye produces retinal degeneration that is not rescued by p35 (7) . Differences in the expression systems used by the 2 groups could account for the inconsistency of p35 rescue. Alternatively, the differential effect of p35 may indicate that polyglutamine expansions act via different mechanisms depending on their protein contexts. Protein context must play an important role in the polyglutamine disorders, because distinct clinical and pathologic syndromes are produced by polyglutamine expansions within different proteins showing widespread, overlapping expression patterns (reviewed in 9).
Similar experiments have been carried out in C. elegans. Faber et al. (8) expressed expanded and unexpanded forms of huntingtin in nematode sensory neurons. They observed huntingtin-induced neuronal degeneration, but only after coexpression of another toxic protein. Induction of degeneration also required very long trinucleotide expansion. In C. elegans, 150 repeat, but not 95 repeat mutations caused neurodegeneration. In humans, more than about 38 repeats usually produces disease, and a repeat length of 95 would be expected to produce severe, juvenile onset Huntington disease. ced-3 caspase function was required for neurodegeneration, implicating apoptosis as the mechanism of cell death.
Protein aggregation and formation of nuclear inclusions are prominent features of human and transgenic mouse pathology in polyglutamine expansion diseases. Both Drosophila and C. elegans develop abnormal protein aggregates, but only the Drosophila models show nuclear localization of the aggregated protein (Fig. 2D ) (6) (7) (8) . In both mice and Drosophila, inclusion formation precedes detectable pathology (6, 7, 10) . In contrast, a functional assay for sensory neuron function in C. elegans reveals neuronal dysfunction before cytoplasmic protein aggregates are seen. Although nuclear inclusions are a prominent feature of polyglutamine diseases in humans, mice, and flies, the relationship of inclusion formation to disease pathogenesis remains a subject of debate. Recent work in transgenic mice (11) and cell culture (12) has shown that polyglutamine containing proteins can induce neuronal dysfunction in the absence of large nuclear aggregates. It remains to be determined if toxicity requires formation of smaller aggregates not readily detectable at the light microscopic level.
Invertebrate models may not only reproduce key aspects of human disorders, but may also suggest new hypotheses regarding the pathogenesis of the human disease. Expression of expanded ataxin-1 in Drosophila produces abnormalities in retinal (Fig. 2C ) and other tissues (4), consistent with results with other mutant polyglutamine-containing proteins. Unexpectedly, however, unexpanded ataxin-1 is also quite toxic (Fig. 2B) . Normal sequence ataxin-1 may have neurotoxic properties unrelated to the polyglutamine expansion. Expression of unexpanded ataxin-1 does not have a toxic effect on mouse Purkinje cells. Unexpanded ataxin-1 may be toxic to Drosophila, but not mice. Alternatively, ataxin-1 toxicity might manifest only with higher concentrations of the protein, or with aggregation. Ataxin-1 toxicity might then play a role in human disease following aggregation of the protein, alteration of the normal subcellular localization, or increase in concentration. The Drosophila results suggest that expanded ataxin-1 might exert a dominant negative effect. It would be of interest to determine if toxicity of expanded ataxin-1 requires, or is influenced by, the presence of unexpanded protein. A possible dominant negative effect could be tested using mice lacking endogenous ataxin-1.
Thus far, invertebrate models of polyglutamine diseases appear promising: flies and worms expressing mutant proteins show both degeneration of the nervous system and abnormal protein aggregates. However, the major utility of the invertebrate systems is in defining proteins important in the pathogenesis of the human disorders. Two groups have approached the problem with different methods. First, Warrick et al (13) used the candidate approach to test proteins they suspected might be involved in the disease based on current models of disease pathogenesis. These authors showed that expression of the molecular chaperone HSP70 suppresses mutant ataxin-3 induced neurodegeneration in the Drosophila retina. Strikingly, chaperone proteins were also implicated in polyglutamine toxicity using an unbiased genetic approach. Kazemi-Esfarjani and Benzer (14) screened for novel mutations that suppress polyglutamine toxicity in Drosophila. They identified a gene homologous to human heat shock protein 40/HDJ1 and a separate locus that also encodes a predicted chaperone-related J domain. The Drosophila modifier results correlate well with the presence of protein aggregates in polyglutamine diseases and studies in mammalian systems implicating heat shock chaperones polyglutamine diseases (15) .
Alzheimer Disease
The impact of invertebrate work on the polyglutamine expansion diseases has come primarily from animals overexpressing mutant human proteins. In contrast, contributions of invertebrates to the study of Alzheimer disease have obtained almost exclusively from a more traditional approach. Genetic experiments have delineated basic biologic pathways involved in development and normal physiological processes, and these results have been related to Alzheimer disease pathogenesis. Genetic evidence that the presenilins influence Notch signaling provided the first intersection between signaling cascades defined in invertebrates and human neurodegenerative disease. The Notch family of transmembrane receptors mediate a variety of cell interactions during development in Drosophila and C. elegans (reviewed in 16). More than 80% of familial Alzheimer disease cases are linked to mutations in the presenilin genes, which encode multiple transmembrane domain proteins (17) (18) (19) . Presenilins play a key role in Notch signaling. Work in C. elegans first implicated presenilins in Notch functioning. One of the two C. elegans presenilin genes, sel-12, was first defined as a suppressor of a hypermorphic allele of lin-12, a C. elegans Notch protein (20) . Mice with inactivated presenilin or Notch genes show similar malformations (21, 22) . Recently, the role of presenilin in Notch processing has been further defined. Signaling through the Notch receptor requires ligand-dependent cleavage of the Notch protein. Cleavage of the Notch protein occurs within the transmembrane domain, and is presenilin dependent (23) (24) (25) .
Like Notch, processing of the amyloid precursor protein involves cleavage within the transmembrane domain. Many lines of evidence implicate altered regulation of the intratransmembrane cleavage in the pathogenesis of Alzheimer disease. Cleavage within the transmembrane domain of the amyloid precursor protein by gamma-secretase is required to produce a set of peptides 39 to 43 amino acids in length (A␤ peptides) that form the extracellular congophilic amyloid plaques characteristic of Alzheimer disease. Approximately 2% to 3% of familial Alzheimer disease is caused by mutations in the amyloid precursor protein that act to increase A␤. In many systems, presenilin mutations increase A␤ accumulation, and presenilins likely represent gamma secretase (26) .
Although intramembranous proteolysis provides the most obvious analogy between the Notch signaling pathway and neurodegenerative disease, other elements of the same cascade may prove equally relevant. Presenilin associates with beta-catenin and glycogen synthase kinase3beta (GSK-3beta). Both beta-catenin and GSK-3beta are modulated by from the Notch and the related Wingless/ Wnt pathways (reviewed in 27). Presenilin stabilizes beta-catenin. Alzheimer disease associated mutations reduce the stabilization provided by presenilin, and may predispose to beta-amyloid induced apoptosis (28) . In contrast, mutant presenilins bind avidly to GSK-3beta and enhance the ability of the kinase to phosphorylate tau (29) . Phosphorylation of tau by GSK-3beta has been implicated in neurofibrillary tangle formation. Thus, presenilin mutations may have multiple effects in the Notch/ Wingless signaling pathways that predispose to the diverse cellular pathologies associated with Alzheimer disease: neuronal loss, amyloid plaque formation, and development of neurofibrillary tangles.
Mutations in Notch, and the Notch ligand Jagged, have been documented in human disease. CADASIL, or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, is a small vessel vasculopathy characterized by multiple subcortical infarcts and a clinical syndrome that often includes dementia. Missense mutations in Notch3 are present in CADASIL patients (30) . T-cell lymphoblastic leukemia/lymphoma can be associated with translocations at the Notch locus (31) . Jagged mutations cause Alagille syndrome, an autosomal dominant disorder including neonatal jaundice, intrahepatic cholestasis, and developmental anomalies of the liver, heart, vertebrae, eyes, and face (32) .
The Drosophila and C. elegans amyloid precursor protein homologs do not contain sequences homologous to human A␤ (33, 34) . Since production and deposition of A␤ appears central in the development of Alzheimer disease, manipulating the endogenous amyloid precursor protein ortholog in these organisms holds little promise for modeling the human disorder. However, an expression strategy relying on direct toxicity of a human protein does appear useful. Expression of a signal peptide-A␤ fusion construct in C. elegans produces large Congophilic, A␤-rich deposits in muscle (35) . The ability of forced expression of the A␤ peptide to produce an amyloid-like substance in worms has been used to assay the effects of various amino acid substitutions on in vivo amyloid production (36) . If the system can be expanded to monitor neurotoxicity of A␤ as well, the inherent potential of the system to define elements required for A␤ toxicity genetically could be exploited. In addition, the relationship between neurotoxicity and aggregation could be addressed.
Retinitis Pigmentosa
The parallels between retinal degeneration in humans and Drosophila provides one of the best arguments that, despite differences in the organization and function of the nervous system, insights derived from the invertebrate system will be directly applicable to human disease. Mutations in human rhodopsin cause retinal degeneration, or retinitis pigmentosa (37) . Despite clear anatomic and biochemical differences between Drosophila and mammalian eyes, mutations in Drosophila opsin also cause retinal degeneration (38) . Retinal degeneration in fly rhodopsin mutants, and in other Drosophila retinal degeneration mutants as well, can be blocked by expression of the baculovirus anti-apoptotic protein p35 (39) . These findings suggest that modulation of apoptosis may be therapeutic in retinitis pigmentosa.
The phototransduction cascade is initiated through similar photosensitive opsins in mammals and Drosophila. The opsins then influence divergent cellular second messenger cascades. In vertebrates, the light signal activates a heterotrimeric G-protein that then stimulates cGMP phosphodiesterase. Decreased cGMP levels lead to the closure of plasma membrane cation channels and photoreceptor hyperpolarization. In contrast, the light response in Drosophila involves activation of phospholipase C, production of inositol triphosphate, calcium release, and eventual depolarization of the photoreceptor.
Mutations in a number of the proteins involved in the Drosophila phototransduction cascade produce retinal degeneration: phospholipase C (norpA), diacylglycerol kinase (rdgA), phosphatidylinositol transfer protein (rdgB), and a calcium-dependent serine/threonine protein phosphatase (rdgC). Mammalian homologs of many of these proteins have been identified. Mammalian rdgB can substitute functionally for the fly protein, and is specifically expressed in the retina (40) . A number of retinal diseases colocalize genetically with mammalian rdgB (41) . A human retinal-restricted phosphatase, shares unique sequence motifs with rdgC (42) . Despite differences in the phototransduction cascade, homologous proteins are clearly used in the same organ and are attractive disease gene candidates. The parallel with the eyeless/aniridia story is striking (reviewed in 43). Mutations in the Pax-6 transcription factor cause eyeless phenotypes in humans (Aniridia), mice (Small eye), and Drosophila (eyeless). Strikingly, both vertebrate and invertebrate Pax-6 can induce eye formation when expressed ectopically (44) . The same transcription factor directs the development of a homologous organ, despite the marked structural dissimilarities between eyes in flies and people.
''Failures'': Amyotrophic Lateral Sclerosis and Prion Diseases
Attempts have been made to model both amyotrophic lateral sclerosis (ALS) and prion diseases in flies. Both diseases appear to be caused by a toxic dominant gain of function mechanism and appear ideal candidates for modeling in invertebrate systems. However, successful models have not yet been produced. Dominant mutations in the Cu/Zn superoxide dismutase (SOD) gene cause about 20% of familial ALS (reviewed in 45). Several lines of evidence support a novel toxic gain of function mechanism for pathogenic SOD mutations. Expression of mutant SOD proteins in transgenic mice creates a motor neuron degeneration syndrome with many similarities to the human disease. Mice with no endogenous Cu/Zn SOD are healthy and have no spontaneous abnormality of motor neurons. Some SOD-linked mutant proteins can inhibit the activity of normal SOD, but a dominant gain of function mechanism of disease pathogenesis appears unlikely because neuron disease produced by expression of mutant SOD is not influenced by endogenous SOD protein. Progression and pathologic features of the disease are the same regardless of levels of normal SOD. The precise nature of the toxicity endowed by ALS-linked mutations remains unclear. Increased peroxidase activity of mutant enzymes has been described, and may relate to motor neuron dysfunction (46) .
Modeling SOD-related pathologies in invertebrates appears an attractive prospect. Both C. elegans and Drosophila have clear Cu/Zn SOD orthologs. A bovine transgene can rescue SOD null mutations in Drosophila (47) , showing functional as well as sequence homology. In both organisms, SOD can clearly influence the regulation of lifespan (48, 49) . Missense mutations in Drosophila SOD produce neurodegeneration (50) . The retinas of flies carrying a biochemically null SOD missense mutation develop normally, but show marked degeneration of neuronal and nonneuronal cells after 7 days. Effects on motor neurons and other areas of the nervous system were not reported, nor was the presence of inclusion bodies. Point mutations, but not deletions, show biochemical evidence of a dominant negative effect. However, unlike murine ALS models, normal SOD rescues, rather than enhances, the phenotypic abnormalities seen in the mutant flies. Endogenous point mutations in the Drosophila SOD gene cause neurodegeneration, a feature of ALS. In addition, mutant enzymes show a dominant negative biochemical effect that is observed in selected human disease-linked SOD mutations. Overall, however, mutations in the endogenous fly SOD gene fail to replicate key aspects of the human disease. The fly mutations are recessive and there is no evidence for a toxic effect of the mutant proteins independent of the normal SOD enzyme. Drosophila SOD may be different enough from the human enzyme that analogous toxic properties cannot be endowed on the fly enzyme. Alternatively, the genetic selection used to isolate the Drosophila mutants may bear little relationship to the factors producing pathogenic human mutations.
If human mutations are indeed a special set of genetic alterations endowing a specific toxic property on the abnormal enzymes, expressing the mutant human SOD might model ALS in invertebrates. Transgenic mice expressing disease-linked SOD mutant proteins develop a motor neuron degeneration syndrome that resembles ALS. One human mutant protein has been expressed in Drosophila (51). The G41S mutation was expressed in Drosophila motor neurons using the control of elements specific for motor neurons. No abnormalities were detected in flies producing the human mutant. The results were not altered by the presence or absence of endogenous Drosophila SOD, or by the transgenic expression of normal human SOD. Interestingly, Drosophila lifespan can be increased by expression of normal human SOD selectively in motor neurons (52) . Motor neuron senescence may be a key factor limiting fly survival, and by analogy other organisms as well. Like the normal protein, human SOD carrying the disease-linked G41S mutation increases fly lifespan.
In contrast to the results modeling polyglutamine disorders in invertebrates by expressing a toxic human protein, the Drosophila ALS model appears disappointing. Neither mutations in the endogenous fly SOD gene nor expression of a toxic human transgenes recapitulate key features of the human disorder. However, before abandoning the invertebrate approach to ALS entirely, several points should be addressed. First, only a single SOD mutant was assayed in Drosophila. Age of onset and severity of disease vary substantially in transgenic mice expressing different disease-linked SOD mutations. Given the short life spans of flies and worms, and the many other differences between flies, worms, and people, a ''supertoxic'' SOD mutant might be required to model ALS. In C. elegans, a very long repeat length Huntingtin allele is needed to produce effects. Second, expression of mutant SOD might be more toxic in other tissues. Although the primary pathology in ALS involves upper and lower motor neurons, the cell type in which mutant SOD exerts its effects is unclear. Of course, cofactors necessary for the development of human disease may simply be absent or inadequately conserved in invertebrates. Perceived and actual differences between the nervous systems of mammals and invertebrates have limited the application of simple genetic systems to human disease in the past and represent a legitimate concern.
As for many of the neurodegenerative disorders discussed above, prion protein pathogenesis probably also involves a toxic, novel property of the abnormal protein. However, at least 1 attempt to model spongiform encephalopathy in Drosophila was unsuccessful (53) . Expression of wild type Syrian hamster prion protein produced no detectable phenotype in flies. In addition, no protease resistant protein was seen. Prion proteins from other species, and mutant forms of prion proteins, might prove more toxic. In the experiments expressing hamster prion protein in flies, repeated heat shocks were used to drive expression of a transgene controlled by a heat shock promotor. An expression system that does not rely on heat shock may be more suitable because induced heat shock proteins could act as chaperones to mitigate the effect of abnormally folded proteins.
Mutations in Invertebrate Genes Producing Neurodegeneration
A number of mutants exist in flies and worms that were selected specifically for adult onset degeneration of the brain. These mutants represent an important complement to transgenic animals created to model specific diseases. One of the most powerful features of genetic analysis is the unbiased nature of the approach. In theory, any gene product that contributes to a particular cellular process should be identifiable by random mutagenesis. Practical limitations include cases in which mutations of 1 copy of a gene are lethal, and are therefore difficult to recover. Genetic redundancy represents a more common limitation. Functional complementation by related proteins may mask relevant phenotypes, even though the encoded gene product is important in the process being studied. In spite of these caveats, genetic dissection remains one of the best methods of nonhypothesis driven analysis.
The Drosophila mutant bubblegum is the only mutant selected for neurodegeneration that has shown a biochemical or molecular relationship to a human disease gene product (54) . bubblegum was originally isolated on the basis of reduced lifespan. Histologic analysis of the brain reveals degeneration of the retina and optic lobes. The visual system is normal at eclosion, but over time axonal swelling, neuropil vacuolization, and cell loss are seen. Cloning the bubblegum gene revealed a connection to human disease. bubblegum corresponds to very long chain fatty acid (VLCFA) acyl coenzyme A synthetase. Intriguingly, reduced VLCFA acyl coenzyme A synthetase activity is present in adrenoleukodystrophy patients. Very long chain fatty acid levels are elevated in bubblegum flies. In addition, feeding flies with monounsaturated fatty acids (''Lorenzo's oil'') normalized VLCFA levels, as is seen in patients with adrenoleukodystrophy. Remarkably, feeding the same fatty acids to developing flies not only decreased VLCFA levels, but prevented neurodegeneration as well. Attempts to prevent or retard manifestations of adrenoleukodystrophy in patients by lowering VLCFA levels have so far been unrewarding.
Given the biochemical similarities, bubblegum has been proposed as a model for adrenoleukodystrophy. Similarities between the Drosophila mutant and the human disease include elevation of VLCFAs, normalization of fatty acid levels with dietary treatment, and loss of VLCFA acyl coenzyme A synthetase activity. However, VLCFAs are increased in not only adrenoleukodystrophy, but in 9 of 15 other known peroxisome disorders, including Zellweger's syndrome, acyl coenzyme A oxidase deficiency, and neonatal adrenoleukodystrophy. Adrenoleukodystrophy is not linked genetically to VLCFA acyl coenzyme A synthetase. Instead, mutations in a transmembrane transporter of the ABC superfamily whose function and substrate specificity cause the disease. There is no apparent correlation between VLCFA levels in patients (or mice with inactivation of the corresponding ABC-type transporter) and disease symptoms, progression, or neuropathology. Finally, the pathology of the Drosophila mutants bears little resemblance to the human disorder. Adrenoleukodystrophy manifests as a disease of myelinating glia in the central and peripheral nervous system. Neuronal loss occurs late in the human disorder and may be secondary to white matter damage. Ultrastructural examination of tissue from patients with adrenoleukodystrophy reveals characteristic trilaminar inclusions composed of accumulated fatty acids. Similar structures were not observed in the bubblegum mutant flies. bubblegum mutants do show peroxisomal dysfunction associated with neuronal degeneration. Perhaps the mutant may best serve as a general model of peroxisomal disorders. Prevention of neurodegeneration in the fly model by biochemical normalization suggests that the strategy may eventually be successful a human disease, despite the poor results to date.
Direct examination of brain histology has also been used to isolate Drosophila neurodegeneration mutants. The swiss cheese mutant appeared in a screen for mutants showing anatomical brain defects in the adult fly (55) . Histologic sections show widespread vacuoles that increase in number over time. Lifespan is decreased by approximately two thirds to one half in various mutant alleles. The first ultrastructural abnormality seen is abnormal, multilayered wrapping of neurons by glial processes. Subsequently, neuronal loss and widespread neuropil vacuolization occurs. Although the initial pathology present in swiss cheese mutant flies is glial, the gene product is present primarily in neurons (56) . The glial abnormalities observed could be secondary to neuronal pathology. In humans, concentric Schwann cell hypertrophy, or so-called ''onion bulb'' formation, is prominent in primary disorders of the myelin sheath like CharcotMarie-Tooth disease. However, concentric hypertrophy is a nonspecific response to injury that may be seen in a wide range of acquired and inherited disorders.
The swiss cheese gene encodes a novel protein with 2 domains homologous to the regulatory subunit of protein kinase A. The swiss cheese protein also shows similarity to human neuropathy target esterase, a protein implicated in neuronal degeneration produced by organophosphates. Although the precise role of the protein remains unclear, these studies strongly implicate the swiss cheese protein in the neurodegenerative process.
Glial abnormalities have also been documented in the Drosophila neurodegenerative mutant drop-dead (57) . Glia in drop-dead mutant brains demonstrate shortened cell processes rather than the excess wrapping observed in the swiss cheese mutant. As for swiss cheese mutants, glia in drop-dead flies are affected prior to the onset of neuronal loss. The nature of the protein encoded by the drop-dead locus, and its expression pattern, will be help define the precise role of glial pathology to neurodegeneration in the drop-dead mutant. It is intriguing that 2 independently isolated Drosophila neurodegeneration mutants appear to exert their primary effect on glial cells. These results suggest that brain degeneration in Drosophila may be fundamentally different in some aspects than central nervous system degenerations in humans. Alternatively, perhaps early glial pathology should be reevaluated in common human neurodegenerative diseases.
C. elegans has provided one of the most satisfying models of neurodegeneration from the mechanistic point of view. Dominant mutations in 3 worm genes, deg-1, mec-4, and mec-10, cause degeneration of touch-receptor neurons (58) . The 3 C. elegans degenerin genes encode proteins with homology to subunits of amiloride-sensitive sodium channels found in epithelia and various types of neurons. Identification of the degenerins as channel components suggested that cell death results from dysregulated ion flux through the mutant channels. This hypothesis is supported by the observation that mammalian degenerin is activated by mutations causing degeneration in C. elegans (59) . Mammalian degenerin remains an attractive disease gene candidate, but no linkage to a human disorder has yet been reported.
Ion channel abnormalities can also produce muscle disease in worms and humans. The C. elegans degenerin unc-105 forms cation ion channels. These channels are activated by mutations that cause muscle degeneration or hypercontraction (60) . Although a direct unc-105 mammalian homolog has not been described, a variety of human myopathies, including hyperkalemic periodic paralysis and myotonia congenita, are caused by mutations in ion channels. 
Summary
Promising new models now exist for neurodegeneration diseases in flies and worms. The most successful models have used direct expression of toxic human proteins in invertebrate organisms to model the cognate human disorders. These models faithfully replicate many aspects of the human syndromes and provide great promise for further genetic dissection of fundamental pathogenetic mechanisms. In addition, small, short-lived flies and worms may be ideal drug testing substrates. As the biochemical and cell biological similarities between vertebrates and invertebrates continue to emerge, additional fly and worm disease models will doubtless continue to enrich the study of neurodegenerative disease.
